Free Trial

Panbela Therapeutics (PBLA) Competitors

Panbela Therapeutics logo
$0.05 0.00 (0.00%)
As of 09/12/2025

PBLA vs. SRNE, LIPO, VRAX, ELAB, CANF, PTIX, GLMD, UPC, VAXX, and ATXI

Should you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Sorrento Therapeutics (SRNE), Lipella Pharmaceuticals (LIPO), Virax Biolabs Group (VRAX), PMGC (ELAB), Can-Fite BioPharma (CANF), Atrinsic (PTIX), Galmed Pharmaceuticals (GLMD), Universe Pharmaceuticals (UPC), Vaxxinity (VAXX), and Avenue Therapeutics (ATXI). These companies are all part of the "pharmaceutical products" industry.

Panbela Therapeutics vs. Its Competitors

Panbela Therapeutics (NASDAQ:PBLA) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

4.4% of Panbela Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 0.0% of Panbela Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Panbela TherapeuticsN/A N/A -302.61%
Sorrento Therapeutics N/A N/A N/A

Panbela Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

In the previous week, Panbela Therapeutics' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company Overall Sentiment
Panbela Therapeutics Neutral
Sorrento Therapeutics Neutral

Panbela Therapeutics has higher earnings, but lower revenue than Sorrento Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Panbela TherapeuticsN/AN/A-$25.26M-$71.130.00
Sorrento Therapeutics$60.32M0.03-$572.84MN/AN/A

Summary

Panbela Therapeutics and Sorrento Therapeutics tied by winning 3 of the 6 factors compared between the two stocks.

Get Panbela Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PBLA vs. The Competition

MetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$243K$736.37M$5.84B$10.14B
Dividend YieldN/A4.84%5.68%4.60%
P/E Ratio0.001.1775.4125.98
Price / SalesN/A26.64515.81181.13
Price / CashN/A19.5637.5660.44
Price / Book0.006.6812.156.29
Net Income-$25.26M-$4.13M$3.29B$271.07M
7 Day PerformanceN/A8.45%0.74%3.87%
1 Month PerformanceN/A9.54%5.00%5.49%
1 Year PerformanceN/A23.90%62.53%25.86%

Panbela Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PBLA
Panbela Therapeutics
0.0669 of 5 stars
$0.05
flat
N/AN/A$243KN/A0.006
SRNE
Sorrento Therapeutics
0.9143 of 5 stars
$0.01
-16.7%
N/A-22.2%$2.76M$60.32M0.00800Gap Down
LIPO
Lipella Pharmaceuticals
1.9389 of 5 stars
$0.59
+0.0%
N/A-80.2%$2.73M$536.36K-0.144Short Interest ↓
VRAX
Virax Biolabs Group
2.2346 of 5 stars
$0.57
-5.7%
$3.00
+425.3%
-77.0%$2.63M$10K0.005News Coverage
Short Interest ↑
Gap Down
ELAB
PMGC
0.8449 of 5 stars
$4.66
-17.8%
N/A-99.7%$2.41M$1.71M-0.0118Short Interest ↓
Gap Down
CANF
Can-Fite BioPharma
1.9037 of 5 stars
$0.66
+4.9%
$14.50
+2,089.7%
-72.4%$2.34M$674K-0.378Short Interest ↑
PTIX
Atrinsic
0.5372 of 5 stars
$3.59
-0.3%
N/A-70.9%$2.12MN/A-0.272Positive News
Earnings Report
Analyst Upgrade
Short Interest ↑
GLMD
Galmed Pharmaceuticals
0.9275 of 5 stars
$1.27
flat
N/A-63.3%$2.10MN/A-0.0820Short Interest ↑
UPC
Universe Pharmaceuticals
0.9564 of 5 stars
$3.51
-1.1%
N/AN/A$2M$23.02M0.00220Short Interest ↓
VAXX
Vaxxinity
N/A$0.02
-65.9%
N/A-95.0%$1.90MN/A-0.0390Gap Down
ATXI
Avenue Therapeutics
1.212 of 5 stars
$0.58
+1.8%
N/A-70.8%$1.85MN/A0.034Gap Up

Related Companies and Tools


This page (NASDAQ:PBLA) was last updated on 9/14/2025 by MarketBeat.com Staff
From Our Partners